Preclinical development of human cells for potential therapeutic application in neurodegenerative diseases requires that their long-term survival, stability and functional efficacy be studied in animal models of human disease. Here we describe a strategy for long-term immune protection of human fetal and stem cell-derived neural cells transplanted into the adult rat brain, by desensitizing the host rat to similar cells in the neonatal period, without the need for additional immunosuppression.
An important stage in the preclinical evaluation of human cells for transplantation in neurodegenerative disease has been to validate the survival, safety and functional efficacy of the selected cells by (xeno)transplantation into experimental animal models of the disease [1] [2] [3] [4] [5] [6] [7] . Without appropriate immunosuppression, neural xenografts in the adult rat or mouse brain are rejected within 2-4 weeks 2, 3, 8 . Immunosuppression is typically achieved either by the administration of immunosuppressant drugs 2, 3, 9 or by using immunologically incompetent genetic mutants as the host 10 . However, neither method permits repeated behavioral testing over long survival times. Here we present a strategy to achieve long-term survival of human neural grafts in the adult mammalian brain, based on desensitizing host rats to the xenogeneic donor cells during the neonatal period.
Experimental groups are detailed in Table 1 . All experimental and surgical procedures were conducted under the UK Animals (Scientific Procedures) Act 1986, and subject to local ethical review and the relevant personal, project and institution licenses. All host animals were rats. Donor tissue was from either human or mouse primary fetal (hPF or mPF, respectively) brain tissue or fetal brainderived neural precursors (hFNPs or mFNPs, respectively), or human embryonic stem cell-derived neural precursor (hES-N) cells. Human fetal tissues were collected by donation of the products of elective termination of pregnancy, within the MRCsponsored South Wales Initiative for Fetal Tissue Transplantation ('SWIFT') programme, with ethical approval from the Bro Taf Local Research Ethics committee. Groups 1-4 were controls, which confirmed the rapid xenograft rejection in the absence of immunosuppression (groups 1 and 2; Fig. 1a ) and approximately 75% survival rates after daily injections of cyclosporine A (groups 3 and 4; Fig. 1b) , but with progressive emergence of side effects consistent with previous findings 2, 3, 8 .
We investigated the concept of desensitizing rat neonates to a subsequent xenotransplant of neural tissues in adulthood using mouse (groups 5 and 6) as well as human (all subsequent groups) donor cells. In all cases we injected a cell suspension of 100,000 cells ml -1 intraperitoneally on the day of birth (Supplementary Methods online). We allowed the pups to mature to 10-12 weeks of age at which point we implanted similar preparations of 250,000-500,000 cells unilaterally into the cerebrum (striatum). Using this technique, implanted mPF cells (group 5) and mFNPs (group 6) both resulted in surviving grafts (11/15 and 11/13 rats, respectively), containing similar numbers of cells (Newman-Keuls post-hoc comparison, t, between the two groups; t 20 ¼ 0.62, not significant) and neurons (t 20 ¼ 0.59, not significant).
Human xenografts of cortical (group 7) or striatal (group 8) primary fetal cells derived from human embryos of 6-10 weeks gestational age, yielded surviving grafts at 25 or 40 weeks (48/55 and 10/15 surviving grafts in rat hosts, respectively; Fig. 1c,d ) after transplantation. The grafted cells we used were obtained from a different maternal donor to those used for desensitization. Stereological analysis of graft neuronal number showed no significant difference (Po0.25) with the increased survival time from 25 to 40 weeks (t 55 ¼ 0.79, not significant). CsA-treated rats became unwell at 12 weeks and had to be killed in accordance with the rules of the animal license; graft survival could therefore not be assessed beyond this time.
A suggestion in the literature that hFNPs may be less immunogenic than hPF brain cells 11, 12 (although they also do not survive in the long term in the absence of immunosuppression 12 ) raised a question about the suitability of hFNPs for this approach. We used 10-day expanded hFNPs prepared from 6-10 week old fetal cortex for neonatal desensitization and transplanted a similar fresh preparation of hFNPs into the desensitized hosts at 10-12 weeks of age. Ten of 13 grafts survived at 12 weeks (group 9), comparable to the survival of hPF cells (t 68 ¼ 1.25, not significant; Fig. 1b,c) .
We determined whether further improved survival might be achieved when using the exact same tissue source for neonatal desensitization and subsequent adult implantation; fetal brainderived neural precursors are amenable to cryopreservation, which allows a single population of cells to be used for both, and could address the concern that the population characteristics of fetal brain-derived neural precursor drifts over time in culture 13 . We divided a preparation of cortical hFNPs, with one aliquot used for neonatal desensitization, and the other frozen in liquid nitrogen and thawed 8 weeks later for transplantation back into the same desensitized hosts. These grafts resulted in less survival, with only 6 of 12 grafts surviving (group 10) in the rat host. The number of grafted cells were significantly lower than when we used freshly prepared cells as donors (t 14 ¼ 4.26, P o 0.001; group 9), most likely because of the trauma associated with cryopreservation.
We tested whether neonatal desensitization also applies to hES-N cells 14 . The cells we used first for neonatal desensitization were then maintained in culture for subsequent transplantation into the same host rats in adulthood (group 11). This resulted in 75% graft survival (9/12 rats); the grafts contained similar numbers of human nuclear antigen (HuNu+) cells to those in hPF and fresh hFNP grafts (F 3,45 ¼ 0.11, not significant; Supplementary Fig. 1 online) .
There was no profound difference in graft morphology between cyclosporine A-treated host rats and those desensitized as neonates (Fig. 1e) . Furthermore, in no case did surviving grafts implanted into desensitized hosts show evidence of ongoing rejection; in contrast to non-desensitized hosts, grafts in desensitized rats did not stain for the immune system markers OX42, CD8, CD4 and C3 ( Supplementary Fig. 2 online) . The xenograft survival rates we observed for hPF, hFNP and hES-N cells with neonatal desensitization were comparable with the best results obtained with chronic pharmacological immunosuppression (F 4,124 ¼ 0.26, not significant). However, in contrast to the desensitization model, pharmacological immunosuppression does not allow long-term survival of the rat and does not match the frequently achieved 100% survival we routinely observed with intracerebral allografts in rats or mice, regardless of cell source. Across all groups in which human donor cells were used, whether desensitized or cyclosporine A-treated, the numbers of cells in the graft were approximately 40% of the number transplanted, a fact common across transplantation experiments 15 . The exceptions to this were the cryopreserved hFNPs and the mouse donor cells, which showed significantly lower survival rates than other human neural xenografts (F 5,163 ¼ 24.05, P o 0.01).
We investigated how similar the cells used for neonatal desensitization need to be to those subsequently transplanted into the adult central nervous system. We observed equivalent graft survival and graft cell numbers from hPF cells implanted in rats desensitized with either hFNP or with hPF cells (group 12, 11/13 grafts versus group 7, 48/55 grafts) and vice versa (group 13, 11/14 grafts versus group 9, 10/13 grafts). The survival was directly comparable for all heterotypic (where the cells used for desensitization and transplantation were different) and homotypic groups (where the cells used for desensitization were similar to those used for transplantation) (F 4,163 ¼ 0.006, not significant). In another experiment, we desensitized neonatal rats with a different human tissue (fetal liver), which yielded the poorest graft survival rate (8/13 rats) of any of the combinations investigated and with fewer cells per surviving graft (group 14; F 5,163 ¼ 5.18, P o 0.001). However, the observation that 450% of the grafts survived suggested that considerable (albeit not optimal) desensitization may be provided by diverse tissue sources.
To define the time period over which effective desensitization might be achieved, we inoculated rat pups intraperitoneally with 
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cortical hPF cells on the day of birth or at 5, 10 and 60 days of age, before intrastriatally transplanting them in adulthood (8-12 weeks after desensitization) with striatal hPF cells. Surviving grafts (10/12 and 9/11 rats, groups 15 and 16, respectively) were seen in the rats desensitized up to 5 d after birth, but not in the rats desensitized at 10 d of age (0/9 rats) or in adulthood (0/6 rats) (groups 15-18, F 3,30 ¼ 44.25, P o 0.001). Thus, the effective window for desensitization corresponds to the immediate postnatal period, when the immune system is completing recognition of self. In addition to experimental groups 1 and 2, which indicate no long-term graft survival in the absence of immunosuppression, experimental groups 17 and 18 confirmed that grafts did not survive in the absence of effective early desensitization.
To determine whether antigens present in dead cells are sufficient to achieve full desensitization, we heat-and freeze-treated cortical hPF cells before inoculation. This did not provide any effective desensitization of adult transplants (group 19).
Finally, we determined whether xenografted human striatal cells surviving in desensitized hosts can contribute to striatal lineages in desensitized hosts. Rats neonatally desensitized with striatal hPF cells received intrastriatal transplants in adulthood of striatal hPF cells. By 25 weeks, the grafts contained HuNu + (human) cells, which also immunoreacted to b-tubulin (neurons ; Fig. 1f) ; GFAP (astrocytes ; Fig. 1g) ; DARPP-32, the accepted marker of mature striatal medium spiny neurons (Fig. 1h) ; and GABA, the most prominent striatal neurotransmitter (Fig. 1i) . There was no significant difference in the percentage of neurons across the four groups receiving human cell transplants (P o 0.16; Fig. 1b) , with equivalent results in immunosuppressed and in desensitized animals.
Here we demonstrated that neonatal desensitization not only provides long-term survival of human neural xenografts in otherwise immunologically competent hosts without the need for chronic daily immunosuppression, but also supports appropriate neuronal phenotypic differentiation of transplanted human fetal cells. We performed these experiments in unlesioned hosts; subsequent studies will be needed using relevant models of disease. Because this method does not produce generalized immunosuppression, the host rat remained healthy under normal housing arrangements and full behavioral assessment can be undertaken. This is fundamental for the proper preclinical assessment of functional efficacy of human cells destined for clinical application. Better defining the underlying immunological mechanisms of this desensitization will be the subject of future studies. However, regardless of mechanism, we have empirically defined a powerful tool for the preclinical study of human cell-based therapies in the central nervous system. 
